Identification and Pre-clinical Testing of a Reversible Cathepsin Protease Inhibitor Reveals Anti-tumor Efficacy in a Pancreatic Cancer Model

Overview

Journal Biochimie

Specialty Biochemistry

Date 2010 May 8

PMID 20447439

Citations 22

Authors

Benelita Tina Elie

Vasilena Gocheva

Tanaya Shree

Stacie A Dalrymple

Leslie J Holsinger

Johanna A Joyce

Affiliations

Soon will be listed here.

Abstract

Proteolytic activity is required for several key processes in cancer development and progression, including tumor growth, invasion and metastasis. Accordingly, high levels of protease expression and activity have been found to correlate with malignant progression and poor patient prognosis in a wide variety of human cancers. Members of the papain family of cysteine cathepsins are among the protease classes that have been functionally implicated in cancer. Therefore, the discovery of effective cathepsin inhibitors has considerable potential for anti-cancer therapy. In this study we describe the identification of a novel, reversible cathepsin inhibitor, VBY-825, which has high potency against cathepsins B, L, S and V. VBY-825 was tested in a pre-clinical model of pancreatic islet cancer and found to significantly decrease tumor burden and tumor number. Thus, the identification of VBY-825 as a new and effective anti-tumor drug encourages the therapeutic application of cathepsin inhibitors in cancer.

Citing Articles

Ruthenium-Cathepsin Inhibitor Conjugates for Green Light-Activated Photodynamic Therapy and Photochemotherapy.

Denison M, Garcia S, Ullrich A, Podgorski I, Gibson H, Turro C Inorg Chem. 2024; 63(17):7973-7983.

PMID: 38616353 PMC: 11066580. DOI: 10.1021/acs.inorgchem.4c01008.

A novel system of supported planar endosomal membranes (SPEMs) reveals an enhancing role for cathepsin B in the final stage of Ebola virus fusion and entry.

Odongo L, Habtegebrael B, Kiessling V, White J, Tamm L Microbiol Spectr. 2023; :e0190823.

PMID: 37728342 PMC: 10581071. DOI: 10.1128/spectrum.01908-23.

Hepatitis C virus NS3/4A inhibitors and other drug-like compounds as covalent binders of SARS-CoV-2 main protease.

Andi B, Kumaran D, Kreitler D, Soares A, Keereetaweep J, Jakoncic J Sci Rep. 2022; 12(1):12197.

PMID: 35842458 PMC: 9287821. DOI: 10.1038/s41598-022-15930-z.

A high throughput screening assay for inhibitors of SARS-CoV-2 pseudotyped particle entry.

Xu M, Pradhan M, Gorshkov K, Petersen J, Shen M, Guo H bioRxiv. 2021; .

PMID: 34642691 PMC: 8509088. DOI: 10.1101/2021.10.04.463106.

Recent advances in developing small-molecule inhibitors against SARS-CoV-2.

Xiang R, Yu Z, Wang Y, Wang L, Huo S, Li Y Acta Pharm Sin B. 2021; 12(4):1591-1623.

PMID: 34249607 PMC: 8260826. DOI: 10.1016/j.apsb.2021.06.016.

References

Vasiljeva O, Reinheckel T, Peters C, Turk D, Turk V, Turk B . Emerging roles of cysteine cathepsins in disease and their potential as drug targets. Curr Pharm Des. 2007; 13(4):387-403. DOI: 10.2174/138161207780162962. View

Overall C, Kleifeld O . Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer. 2006; 6(3):227-39. DOI: 10.1038/nrc1821. View

Joyce J, Baruch A, Chehade K, Meyer-Morse N, Giraudo E, Tsai F . Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell. 2004; 5(5):443-53. DOI: 10.1016/s1535-6108(04)00111-4. View

Rowe R, Weiss S . Navigating ECM barriers at the invasive front: the cancer cell-stroma interface. Annu Rev Cell Dev Biol. 2009; 25:567-95. DOI: 10.1146/annurev.cellbio.24.110707.175315. View

Burden R, Snoddy P, Jefferies C, Walker B, Scott C . Inhibition of cathepsin L-like proteases by cathepsin V propeptide. Biol Chem. 2007; 388(5):541-5. DOI: 10.1515/BC.2007.053. View

Yasuda Y, Kaleta J, Bromme D . The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics. Adv Drug Deliv Rev. 2005; 57(7):973-93. DOI: 10.1016/j.addr.2004.12.013. View

Lopez T, Hanahan D . Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. Cancer Cell. 2002; 1(4):339-53. DOI: 10.1016/s1535-6108(02)00055-7. View

Chang S, Kanasaki K, Gocheva V, Blum G, Harper J, Moses M . VEGF-A induces angiogenesis by perturbing the cathepsin-cysteine protease inhibitor balance in venules, causing basement membrane degradation and mother vessel formation. Cancer Res. 2009; 69(10):4537-44. PMC: 2683911. DOI: 10.1158/0008-5472.CAN-08-4539. View

Burden R, Snoddy P, Buick R, Johnston J, Walker B, Scott C . Recombinant cathepsin S propeptide attenuates cell invasion by inhibition of cathepsin L-like proteases in tumor microenvironment. Mol Cancer Ther. 2008; 7(3):538-47. DOI: 10.1158/1535-7163.MCT-07-0528. View

10.

Ribatti D, Nico B, Crivellato E, Roccaro A, Vacca A . The history of the angiogenic switch concept. Leukemia. 2006; 21(1):44-52. DOI: 10.1038/sj.leu.2404402. View

11.

Shi G, Sukhova G, Kuzuya M, Ye Q, Du J, Zhang Y . Deficiency of the cysteine protease cathepsin S impairs microvessel growth. Circ Res. 2003; 92(5):493-500. DOI: 10.1161/01.RES.0000060485.20318.96. View

12.

Gocheva V, Zeng W, Ke D, Klimstra D, Reinheckel T, Peters C . Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev. 2006; 20(5):543-56. PMC: 1410800. DOI: 10.1101/gad.1407406. View

13.

Schurigt U, Sevenich L, Vannier C, Gajda M, Schwinde A, Werner F . Trial of the cysteine cathepsin inhibitor JPM-OEt on early and advanced mammary cancer stages in the MMTV-PyMT-transgenic mouse model. Biol Chem. 2008; 389(8):1067-74. DOI: 10.1515/BC.2008.115. View

14.

Burden R, Gormley J, Jaquin T, Small D, Quinn D, Hegarty S . Antibody-mediated inhibition of cathepsin S blocks colorectal tumor invasion and angiogenesis. Clin Cancer Res. 2009; 15(19):6042-51. DOI: 10.1158/1078-0432.CCR-09-1262. View

15.

Palermo C, Joyce J . Cysteine cathepsin proteases as pharmacological targets in cancer. Trends Pharmacol Sci. 2007; 29(1):22-8. DOI: 10.1016/j.tips.2007.10.011. View

16.

Rousselet N, Mills L, Jean D, Tellez C, Bar-Eli M, Frade R . Inhibition of tumorigenicity and metastasis of human melanoma cells by anti-cathepsin L single chain variable fragment. Cancer Res. 2004; 64(1):146-51. DOI: 10.1158/0008-5472.can-03-1717. View

17.

Gocheva V, Chen X, Peters C, Reinheckel T, Joyce J . Deletion of cathepsin H perturbs angiogenic switching, vascularization and growth of tumors in a mouse model of pancreatic islet cell cancer. Biol Chem. 2010; 391(8):937-45. PMC: 3126667. DOI: 10.1515/BC.2010.080. View

18.

Vasiljeva O, Papazoglou A, Kruger A, Brodoefel H, Korovin M, Deussing J . Tumor cell-derived and macrophage-derived cathepsin B promotes progression and lung metastasis of mammary cancer. Cancer Res. 2006; 66(10):5242-50. DOI: 10.1158/0008-5472.CAN-05-4463. View

19.

Turk B . Targeting proteases: successes, failures and future prospects. Nat Rev Drug Discov. 2006; 5(9):785-99. DOI: 10.1038/nrd2092. View

20.

Nakagawa T, Brissette W, Lira P, Griffiths R, Petrushova N, Stock J . Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice. Immunity. 1999; 10(2):207-17. DOI: 10.1016/s1074-7613(00)80021-7. View